Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 58

1.

Treatment patterns of adjuvant interferon-α2b for high-risk melanoma: a retrospective study of the Grupo Español Multidisciplinar de Melanoma - Prima study.

Espinosa E, Soriano V, Malvehy J, Berrocal A, Martínez de Prado P, Quindós M, Soria A, Márquez-Rodas I, Palacio I, Cerezuela P, López-Vivanco G, Alonso L, Samaniego E, Ballesteros A, Puértolas T, Díaz-Beveridge R, de la Cruz-Merino L, López Castro R, López López R, Stevinson K, Del Barrio P, Tornamira MV, Guillém V, Martín-Algarra S.

Melanoma Res. 2016 Jun;26(3):278-83. doi: 10.1097/CMR.0000000000000254.

2.

BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer.

Karachaliou N, Codony-Servat J, Teixidó C, Pilotto S, Drozdowskyj A, Codony-Servat C, Giménez-Capitán A, Molina-Vila MA, Bertrán-Alamillo J, Gervais R, Massuti B, Morán T, Majem M, Felip E, Carcereny E, García-Campelo R, Viteri S, González-Cao M, Morales-Espinosa D, Verlicchi A, Crisetti E, Chaib I, Santarpia M, Luis Ramírez J, Bosch-Barrera J, Felipe Cardona A, de Marinis F, López-Vivanco G, Miguel Sánchez J, Vergnenegre A, Sánchez Hernández JJ, Sperduti I, Bria E, Rosell R.

Sci Rep. 2015 Dec 7;5:17499. doi: 10.1038/srep17499.

3.

Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile.

González-Martín A, Alba E, Ciruelos E, Cortés J, Llombart A, Lluch A, Andrés R, Álvarez I, Aramendía JM, de la Peña FA, Barnadas A, Batista N, Calvo L, Galve E, García-Palomo A, García-Sáenz JÁ, de la Haba J, López R, López-Vivanco G, Martínez-Jáñez N, de Dueñas EM, Plazaola A, Rodríguez-Lescure Á, Ruiz M, Sánchez-Rovira P, Santaballa A, Seguí MÁ, Tusquets I, Zamora P, Martín M.

Curr Cancer Drug Targets. 2016;16(5):415-28. Review.

PMID:
26278712
4.

[Cost of breast cancer treatment by clinical stage in the Basque Country, Spain].

Arrospide A, Soto-Gordoa M, Acaiturri T, López-Vivanco G, Abecia LC, Mar J.

Rev Esp Salud Publica. 2015 Jan-Feb;89(1):93-7. doi: 10.4321/S1135-57272015000100010. Spanish.

5.

Supervised physical exercise to improve the quality of life of cancer patients: the EFICANCER randomised controlled trial.

Sancho A, Carrera S, Arietaleanizbeascoa M, Arce V, Gallastegui NM, Giné March A, Sanz-Guinea A, Eskisabel A, Rodriguez AL, Martín RA, Lopez-Vivanco G, Grandes G.

BMC Cancer. 2015 Feb 6;15:40. doi: 10.1186/s12885-015-1055-x.

6.

Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies.

Moran T, Wei J, Cobo M, Qian X, Domine M, Zou Z, Bover I, Wang L, Provencio M, Yu L, Chaib I, You C, Massuti B, Song Y, Vergnenegre A, Lu H, Lopez-Vivanco G, Hu W, Robinet G, Yan J, Insa A, Xu X, Majem M, Chen X, de Las Peñas R, Karachaliou N, Sala MA, Wu Q, Isla D, Zhou Y, Baize N, Zhang F, Garde J, Germonpre P, Rauh S, ALHusaini H, Sanchez-Ronco M, Drozdowskyj A, Sanchez JJ, Camps C, Liu B, Rosell R; Spanish Lung Cancer Group; French Lung Cancer Group; Comprehensive Cancer Centre of Drum Tower Hospital in Nanjing.

Ann Oncol. 2014 Nov;25(11):2147-55. doi: 10.1093/annonc/mdu389. Epub 2014 Aug 27.

7.

A new biomarker panel in bronchoalveolar lavage for an improved lung cancer diagnosis.

Uribarri M, Hormaeche I, Zalacain R, Lopez-Vivanco G, Martinez A, Nagore D, Ruiz-Argüello MB.

J Thorac Oncol. 2014 Oct;9(10):1504-12. doi: 10.1097/JTO.0000000000000282.

8.

Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: results from the ABEL study.

Lecumberri R, López Vivanco G, Font A, González Billalabeitia E, Gúrpide A, Gómez Codina J, Isla D, Galán A, Bover I, Domine M, Vicente V, Rosell R, Rocha E.

Thromb Res. 2013;132(6):666-70. doi: 10.1016/j.thromres.2013.09.026. Epub 2013 Sep 27.

PMID:
24491267
9.

Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study.

Pivot X, Gligorov J, Müller V, Barrett-Lee P, Verma S, Knoop A, Curigliano G, Semiglazov V, López-Vivanco G, Jenkins V, Scotto N, Osborne S, Fallowfield L; PrefHer Study Group.

Lancet Oncol. 2013 Sep;14(10):962-70. doi: 10.1016/S1470-2045(13)70383-8. Epub 2013 Aug 19.

PMID:
23965225
10.

Thymidylate synthase expression determines pemetrexed targets and resistance development in tumour cells.

Buqué A, Aresti U, Calvo B, Sh Muhialdin J, Muñoz A, Carrera S, Azkona E, Rubio I, López-Vivanco G.

PLoS One. 2013 May 13;8(5):e63338. doi: 10.1371/journal.pone.0063338. Print 2013.

11.

Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study.

Roy A, Cunningham D, Hawkins R, Sörbye H, Adenis A, Barcelo JR, Lopez-Vivanco G, Adler G, Canon JL, Lofts F, Castanon C, Fonseca E, Rixe O, Aparicio J, Cassinello J, Nicolson M, Mousseau M, Schalhorn A, D'Hondt L, Kerger J, Hossfeld DK, Garcia Giron C, Rodriguez R, Schoffski P, Misset JL.

Br J Cancer. 2012 Jul 24;107(3):435-41. doi: 10.1038/bjc.2012.286. Epub 2012 Jul 5.

12.

Molecular mechanism implicated in Pemetrexed-induced apoptosis in human melanoma cells.

Buqué A, Muhialdin JSh, Muñoz A, Calvo B, Carrera S, Aresti U, Sancho A, Rubio I, López-Vivanco G.

Mol Cancer. 2012 Apr 26;11:25. doi: 10.1186/1476-4598-11-25.

13.

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica.

Lancet Oncol. 2012 Mar;13(3):239-46. doi: 10.1016/S1470-2045(11)70393-X. Epub 2012 Jan 26.

PMID:
22285168
14.

Identification of a biomarker panel for colorectal cancer diagnosis.

García-Bilbao A, Armañanzas R, Ispizua Z, Calvo B, Alonso-Varona A, Inza I, Larrañaga P, López-Vivanco G, Suárez-Merino B, Betanzos M.

BMC Cancer. 2012 Jan 26;12:43. doi: 10.1186/1471-2407-12-43.

15.

Fixed-dose-rate gemcitabine infusion in patients with advanced pancreatic or biliary tree adenocarcinoma.

Mané JM, Sancho A, Muñoz A, Rubio I, Fernández R, Carrera S, Fuente N, Ballesteros D, Casas R, Marrodán I, Mielgo X, López-Vivanco G.

Tumori. 2010 May-Jun;96(3):405-10.

16.

Phase I/II and pharmacokinetic study of intravenous vinflunine in combination with cisplatin for the treatment of chemonaive patients with advanced non-small-cell lung cancer.

Souquet PJ, Krzakowski M, Ramlau R, Sun XS, Lopez-Vivanco G, Puozzo C, Pouget JC, Pinel MC, Rosell R.

Clin Lung Cancer. 2010 Mar 1;11(2):105-13. doi: 10.3816/CLC.2010.n.014.

PMID:
20199976
17.

Blood-based CHRNA3 single nucleotide polymorphism and outcome in advanced non-small-cell lung cancer patients.

Carcereny E, Ramirez JL, Sanchez-Ronco M, Isla D, Cobo M, Moran T, de Aguirre I, Okamoto T, Wei J, Provencio M, Lopez-Vivanco G, Camps C, Domine M, Alberola V, Sanchez JM, Massuti B, Mendez P, Taron M, Rosell R.

Lung Cancer. 2010 Jun;68(3):491-7. doi: 10.1016/j.lungcan.2009.08.004. Epub 2009 Sep 5.

PMID:
19733931
18.

Screening for epidermal growth factor receptor mutations in lung cancer.

Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M, Insa A, Massuti B, Gonzalez-Larriba JL, Paz-Ares L, Bover I, Garcia-Campelo R, Moreno MA, Catot S, Rolfo C, Reguart N, Palmero R, Sánchez JM, Bastus R, Mayo C, Bertran-Alamillo J, Molina MA, Sanchez JJ, Taron M; Spanish Lung Cancer Group.

N Engl J Med. 2009 Sep 3;361(10):958-67. doi: 10.1056/NEJMoa0904554. Epub 2009 Aug 19.

19.

Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression.

Rosell R, Perez-Roca L, Sanchez JJ, Cobo M, Moran T, Chaib I, Provencio M, Domine M, Sala MA, Jimenez U, Diz P, Barneto I, Macias JA, de Las Peñas R, Catot S, Isla D, Sanchez JM, Ibeas R, Lopez-Vivanco G, Oramas J, Mendez P, Reguart N, Blanco R, Taron M.

PLoS One. 2009;4(5):e5133. doi: 10.1371/journal.pone.0005133. Epub 2009 May 5.

20.

Prognostic factors in cancer of unknown primary site.

Muñoz A, Fuente N, Rubio I, Ferreiro J, Martínez-Bueno A, López-Vivanco G.

Clin Transl Oncol. 2008 Jan;10(1):64-5. No abstract available.

PMID:
18208796
Items per page

Supplemental Content

Loading ...
Write to the Help Desk